Preclinical studies targeting Wnt/β-catenin signaling, involving small-molecule inhibitor PKF115-584 to block the TCF/β-catenin complex and doxycycline-triggered β-catenin suppression via shRNA, demonstrated reduced tumor cell proliferation and triggered apoptosis in cell culture studies, along with full inhibition of tumor growth in vivo. This evidence concerns the gene HNF4A and neoplasm.